(NASDAQ: ROIV) Roivant Sciences's forecast annual revenue growth rate of 237.63% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.55%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.46%.
Roivant Sciences's revenue in 2026 is $13,310,000.On average, 12 Wall Street analysts forecast ROIV's revenue for 2026 to be $7,265,797,943, with the lowest ROIV revenue forecast at $5,400,680,780, and the highest ROIV revenue forecast at $9,543,874,662. On average, 12 Wall Street analysts forecast ROIV's revenue for 2027 to be $35,300,527,180, with the lowest ROIV revenue forecast at $5,611,096,914, and the highest ROIV revenue forecast at $167,917,800,763.
In 2028, ROIV is forecast to generate $439,419,027,084 in revenue, with the lowest revenue forecast at $142,531,881,434 and the highest revenue forecast at $828,066,215,509.